The Division of Pediatric Hematology-Oncology, Doernbecher Children's Hospital and The Knight Cancer Institute, at Oregon Health & Science University (OHSU), in Portland, Oregon, are seeking laboratory-based scientists and physician investigators focused on pediatric oncology to join our growing team at the assistant/associate professor level.
Research. The majority of your time and effort (minimum 0.8 FTE) will be dedicated to developing your laboratory research program relevant to pediatric cancers. Your primary appointment will be within the Department of Pediatrics, Division of hematology/oncology, and you will receive a secondary appointment in the Division of Oncological Sciences and become a member of the Knight Cancer Institute and as such you will participate in research activities within both divisions.
Education. OHSU is a teaching facility and you will have the opportunity to teach graduate students, medical students, residents and fellows in the research setting as well as through assigned lectures; you will also have the opportunity to mentor graduate students and post-doctoral fellows.
Clinical Activity. For MD and MD/PhD only, clinical activity within the division of pediatric hematology/oncology may be assigned based on needs and your areas of expertise and interest, not to exceed 0.2 FTE effort.
M.D/D.O., MD/PhD, or PhD or equivalent with research focus in pediatric oncology.
The Pediatric Hematology/Oncology Division, within the Department of Pediatrics, as the only academic medical center in Oregon, provides oncology care to patients from across the state. Oregon Health & Science University is a nationally recognized health and research university located in Portland, Oregon. We bring together patient care, research, education of the next generation of health care providers and scientists and community service to improve the health and well-being of all Oregonians and people around the world. The Knight Cancer Institute at OHSU is an international leader in cancer research and precision treatment. The institute's director, Brian Druker, M.D., helped usher in the era of precision cancer medicine with research that led to the breakthrough drug Gleevec®.